E-hospital: Fully coordinated cancer care and research in Europe
E-hospital: Fully coordinated cancer care and research in Europe
The evolving treatment landscape for HER2-positive metastatic breast cancer
ecancermedicalscience editor's choice for July and August 2014
WIN consortium as a basis for forming cross-border collaborations for improving personalised medicine and palliative care
Gdf -11 a new target to improve anaemia in thalassemia
LHRH analogue goserelin helps preserve fertility among women undergoing chemo for hormone receptor-negative breast cancer
Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer
ASCO 2014 roundup
Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer
Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer
Adjuvant exemestane more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer
Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer